Literature DB >> 20066455

Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.

Sotaro Miwa1, Yoshifumi Kadono, Toshiaki Sugata, Atsushi Mizokami, Mikio Namiki.   

Abstract

Here we present a case in which alternation of interferon-alpha (IFN-alpha) treatments was effective in treating pulmonary metastases and lymph node metastases from renal cell carcinoma (RCC). A 56-year-old man underwent left radical nephrectomy under the diagnosis of left RCC. The histological diagnosis was clear cell carcinoma G2, IFN-alpha, pT1b. He subsequently underwent two operations for right pulmonary metastasis and right hilar lymph node metastasis. Postoperatively he was treated with intramuscular administration of natural IFN-alpha (Sumiferon) which prevented definite recurrence for 1 year. However, multiple pulmonary metastases and left hilar lymph node metastasis occurred 11 months after discontinuation of Sumiferon. Therefore, treatment with another natural IFN-alpha (OIF) was started. Although OIF was continued for 7 months, pulmonary metastases and left hilar lymph node metastasis continued to progress. Therefore, treatment was changed to Sumiferon, after which the pulmonary metastases and left hilar lymph node metastasis decreased in size. The metastases showed no progression for 16 months after switching from OIF to Sumiferon.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066455     DOI: 10.1007/s10147-009-0003-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  8 in total

1.  Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells.

Authors:  T Yamaoka; S Kojima; S Ichi; Y Kashiwazaki; T Koide; Y Sokawa
Journal:  J Interferon Cytokine Res       Date:  1999-12       Impact factor: 2.607

2.  Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations.

Authors:  Mototsugu Oya; Hirotaka Asakura; Ryuichi Mizuno; Ken Marumo; Masaru Murai
Journal:  Biomed Res       Date:  2005-06       Impact factor: 1.203

3.  Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro.

Authors:  Y Yanai; S Horie; K Yamamoto; H Yamauchi; H Ikegami; M Kurimoto; T Kitamura
Journal:  J Interferon Cytokine Res       Date:  2001-12       Impact factor: 2.607

4.  [Case report of advanced renal cancer that showed different responses to the alteration of therapeutic cytokines].

Authors:  Yuji Kato; Yuji Saga; Jun-ichi Hori; Hiroshi Hashimoto; Hidehiro Kakizaki
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  2006-03

5.  [Advanced renal cell carcinoma showing a different response to two types of interferon-alpha].

Authors:  Akio Horiguchi; Atsushi Uchida
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  2004-01

6.  Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases.

Authors:  Manabu Tatokoro; Yasuhisa Fujii; Satoru Kawakami; Naotaka Fukui; Yoshinobu Komai; Kazutaka Saito; Fumitaka Koga; Shinji Morimoto; Iwao Fukui; Kazunori Kihara
Journal:  Int J Urol       Date:  2008-09       Impact factor: 3.369

7.  Pulmonary resection of metastatic renal cell carcinoma.

Authors:  R J Cerfolio; M S Allen; C Deschamps; R C Daly; S L Wallrichs; V F Trastek; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1994-02       Impact factor: 4.330

8.  Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology.

Authors:  Kogenta Nakamura; Kazuhiro Yoshikawa; Yoshiaki Yamada; Shinsuke Saga; Shigeyuki Aoki; Tomohiro Taki; Motoi Tobiume; Toru Shimazui; Hideyuki Akaza; Nobuaki Honda
Journal:  Int J Oncol       Date:  2006-04       Impact factor: 5.650

  8 in total
  1 in total

1.  Interferon-α suppresses invasion and enhances cisplatin-mediated apoptosis and autophagy in human osteosarcoma cells.

Authors:  Jun Zhao; Mingli Wang; Zeng Li; Jingxian Chen; Zongshen Yin; Jun Chang; Dongmei Gao; Shiping Wang
Journal:  Oncol Lett       Date:  2013-12-16       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.